6507 ORAL Phase III study of IV vinflunine (VFL) versus IV docetaxel (DTX) in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) previously treated with a platinum-containing regimen

Douillard, Jean-Yves; Coudert, Bruno; Gridelli, Cesare; Mohn-Staudner, Andrea; Salzberg, Bruce; Almodovar, Teresa; Araújo, António; Pujol, J.L.; Riska, Henrik; Depierre, A

doi:10.1016/s1359-6349(07)71335-6

“…Because of its broader spectrum of activity and advantages over other Vinca alkaloids, VFL has been evaluated as monotherapy and as combination chemotherapy in a number of different cancers, including breast cancer, [60][61][62][63][64][65][66] NSCLC, [67][68][69][70][71] small cell lung cancer (SCLC), 72,73 prostate cancer, 74 gastric cancer, 75 malignant pleural mesothelioma [76][77][78] and renal cell carcinoma. 79 The recommended dose for clinical studies is 320 mg/m 2 administered intravenously every 21 days.…”

Section: Clinical Trialsmentioning

confidence: 99%

Critical evaluation of vinflunine in the treatment of refractory metastatic urothelial carcinoma

Talbot¹,

Morel²

2010

OAJU

View full text Add to dashboard Cite

Urothelial carcinoma (UC) accounts for 5% to 10% of malignancies in men in Europe and the United States. For locally advanced or metastatic disease, there are two standard firstline chemotherapy regimens: MVAC (methotrexate, vinblastine, doxorubicin, cisplatin) and gemcitabine/cisplatin. For refractory disease, there is currently no standard treatment. Vinflunine, a second-generation Vinca alkaloid, is the first chemotherapeutic agent to be evaluated in a large UC second-line population. This review discusses the pre-clinical and clinical data published, and compares vinflunine to alternative single agents and combination regimens tested in this setting. Based on the results of the phase II and III clinical trials, there appears to be sufficient evidence to support the use of vinflunine in the second-line setting.

show abstract

“…Because of its broader spectrum of activity and advantages over other Vinca alkaloids, VFL has been evaluated as monotherapy and as combination chemotherapy in a number of different cancers, including breast cancer, [60][61][62][63][64][65][66] NSCLC, [67][68][69][70][71] small cell lung cancer (SCLC), 72,73 prostate cancer, 74 gastric cancer, 75 malignant pleural mesothelioma [76][77][78] and renal cell carcinoma. 79 The recommended dose for clinical studies is 320 mg/m 2 administered intravenously every 21 days.…”

Section: Clinical Trialsmentioning

confidence: 99%

Critical evaluation of vinflunine in the treatment of refractory metastatic urothelial carcinoma

Morel¹,

Talbot²

2010

RRU

2

0

View full text Add to dashboard Cite

Urothelial carcinoma (UC) accounts for 5% to 10% of malignancies in men in Europe and the United States. For locally advanced or metastatic disease, there are two standard firstline chemotherapy regimens: MVAC (methotrexate, vinblastine, doxorubicin, cisplatin) and gemcitabine/cisplatin. For refractory disease, there is currently no standard treatment. Vinflunine, a second-generation Vinca alkaloid, is the first chemotherapeutic agent to be evaluated in a large UC second-line population. This review discusses the pre-clinical and clinical data published, and compares vinflunine to alternative single agents and combination regimens tested in this setting. Based on the results of the phase II and III clinical trials, there appears to be sufficient evidence to support the use of vinflunine in the second-line setting.

show abstract

“…A phase III randomised trial has compared vinflunine, a new vinca alkaloid, 320 mg/m 2 to docetaxel 75 mg/m 2 every 3 weeks in platinum-pretreated advanced NSCLC patients [63]. There was no difference in QoL and clinical activity between the two groups, as well as for median survival (6.7 and 7.2 months in patients treated with vinflunine and docetaxel respectively).…”

Section: New Chemotherapeutic Agentsmentioning

confidence: 99%